Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Imatinib resistance is a major challenge for chronic myeloid leukemia (CML) patients.
• While altered glucose metabolism is noted in resistant cells, mitochondrial impact remains understudied.

Purpose of the Study:

• To investigate and exploit metabolic alterations in imatinib-resistant CML cells.
• To understand the role of mitochondrial dysfunction in imatinib resistance.

Main Methods:

• Comparative analysis of glycolysis and mitochondrial function in imatinib-sensitive and resistant CML cells.
• Assessment of TCA cycle intermediates, NADH levels, oxygen consumption, and ROS production.
• Evaluation of therapeutic interventions targeting glycolysis and oxidative stress in a mouse model.

Main Results:

• Imatinib-resistant cells show increased glycolysis and uncoupled pyruvate oxidation, linked to HIF-1α.
• Mitochondria in resistant cells accumulate TCA intermediates, have elevated NADH, and reduced oxygen consumption.
• Resistant cells exhibit higher ROS production, leading to increased sensitivity to pro-oxidant treatments (PEITC, Trisenox).
• Inhibition of glycolysis in resistant cells restores respiration and reduces ROS.

Conclusions:

• Imatinib-resistant CML cells possess significant mitochondrial dysfunction.
• This dysfunction presents a potential therapeutic vulnerability for selective treatment of resistant CML.